Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761992 | 0.81 | FGFR1 (0.57) | FGFR1HPGDALDH1A1 | |
| SCHEMBL1761632 | 0.80 | FGFR1 (0.56) | FGFR1HPGDALDH1A1MAPK1 | |
| SCHEMBL1761985 | 0.78 | FGFR1 (0.63) | FGFR1HPGDNPSR1HTTNEK2 | |
| SCHEMBL1761799 | 0.75 | HPGD (0.40) | FGFR1HPGDALDH1A1LMNANPSR1 | |
| SCHEMBL1761725 | 0.75 | FGFR1 (0.54) | FGFR1HPGDALDH1A1MAPK1TP53 | |
| SCHEMBL1761648 | 0.74 | FGFR1 (0.63) | FGFR1HPGDALDH1A1 | |
| SCHEMBL7986426 | 0.74 | FGFR1 (1.00) | FGFR1HPGDALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL7975809 | 0.73 | FGFR1 (0.97) | FGFR1HPGDALDH1A1HTT | |
| SCHEMBL1761867 | 0.73 | FGFR1 (0.68) | FGFR1HPGDALDH1A1 | |
| SCHEMBL2662678 | 0.72 | KDR (0.47) | FGFR1HPGDALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288418-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2012-10-16 | — | — | US | disclosed |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885HPGD 1966/4885ALDH1A1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.